1. Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
2. Van Putten MDWC, Heemskerk H, De Kimpe S, et al. Systemic delivery of antisense oligonucleotides restores dystrophin expression and functionality in the mdx mouse. Nice : Congrès AFM-Myologie, 2000, Poster PW26-322.
3. Bilan de l’European Medicines Agency (EMA) établi en avril 2015. Antisense oligonucleotide-mediated exon skipping therapy development for Duchenne muscular dystrophy (DMD). http://exonskipping.eu/wp-content/uploads/2015/04/Briefing-Document-COST-and-SCOPE-DMD-EMA-meeting-April-2015-FINAL-VERSION.pdf